Our current findings underscore the potential of using myeloid cell-targeted STAT3 inhibition to overcome resistance of genitourinary cancers, such as kidney and bladder cancers, to immunotherapy and trigger CD8 T-cell-mediated antitumor immune responses. The gene discussed is STAT3; the disease is urogenital neoplasm.